Biotech earnings into full swing Thursday

by Brett Scott
Sizz's Biotech Blog



Genentech (DNA) started the biotech earnings season on a mixed note last Thursday as second quarter earnings beat the Street's estimates, but its outlook was less than stellar. Biotech might take a backseat to tech bellwethers Microsoft (MSFT) and Google (GOOG) Thursday, but big biotech Gilead reports Thursday and other big biotechs Amylin, Biogen, Genzyme, Celgene and Amgen report next week.

Here is what the Street is expecting from biotech's second quarter.

Gilead (GILD): EPS: $0.39 (39% growth), Revenues: $1.02B (49% growth)
Amylin (AMLN): EPS: $-0.34 (10%), Revenues: $198M (67%)
Biogen (BIIB): EPS: $0.63 (11%), Revenues: $759M (15%)
Genzyme (GENZ): EPS: $0.81 (19%), Revenues: $912M (15%)
Celgene (CELG): EPS: $0.23 (109%), Revenues: $318M (61%)
Amgen (AMGN): EPS: $1.06 (1%), Revenues: $3.69B (2%)



RELATED READING:
- Why Biotech and Not Big Pharma
- The Risks of Small Biotech
- Valuing Biotechs
- Short Squeezing Biotechs
- Strategy for Investing in Small Biotechs
- The Biotech Industry: 30 Years of Failure



Sizz's Biotech Blog is a regular contributor to BioHealth Investor
___________________